S1393
Interdisciplinary - Health economics & health services research
ESTRO 2026
marker X— defined as the number of days when treatment plans were not completed within the scheduled timeframe. Material/Methods: Data were extracted from the MOSAIQ Oncology Management System (Version 2.83, Elekta Inc.), which records all clinical and operational parameters of radiotherapy activity. The dataset included total treatment starts, UHFR starts( breast, prostate ,lung, etc ),NF starts, and the operational marker X — defined as the number of days when treatment plans were not ready on time. For 2025, data covered the period January through July, and values were annualized by extrapolation to reflect full-year trends. Statistical analyses included Pearson correlation, partial correlation, and multiple linear regression (OLS) to evaluate the relationships between UHFR, NF, and X. Standardized regression coefficients ( β ), coefficient of determination (R ² ), and two-tailed p-values were calculated using Python (StatsModels/SciPy), with p < 0.05 considered statistically significant. Results: Between 2021 and 2025 (annualized), total treatment starts rose from 2,691 to 3,217, driven mainly by the expansion of UHFR, which more than doubled (479 to 1,176). NF volumes remained relatively stable (table 1.). Despite maintaining a constant daily patient load, the operational marker X increased from 1651 to 2917, reflecting growing workflow strain (table 2.). Pearson correlation analysis showed a strong positive relationship between UHFR and X (r = 0.75), while NF demonstrated a weak negative association (r = -0.27). Multiple regression analysis yielded an overall explanatory power of R ² = 0.79, with standardized coefficients β (UHFR) = +1.30 (p = 0.12) and β (Normal) = +0.73 (p = 0.28). Partial correlation controlling for NF confirmed a strong link between UHFR and X (r_partial = 0.88, p = 0.12).
Conclusion: The implementation of UHFR protocols has substantially increased treatment capacity and operational throughput. However, the data show that greater UHFR utilization is associated with a rise in the operational marker X, indicating more frequent planning delays. This strong positive association suggests that increased UHFR adoption intensifies pre-treatment workload and planning pressure. These findings highlight the importance of adapting departmental workflows and resource allocation to manage the increased planning and QA demands resulting from UHFR expansion, ensuring that productivity gains do not come at the expense of operational sustainability or treatment quality. References: Rahimi, A., et al. (2022). Hypofractionated Breast Radiation Therapy: A Clinical and Operational Update. Journal of Clinical OncologyChang, J., et al. (2021). The Impact of Hypofractionation on Radiotherapy Service Delivery. Int. J. Radiat. Oncol. Eckstein, J., et al. (2022). Implementation of External Beam Five - Fraction Adjuvant Breast Irradiation in a US Center. CancersBrunt, A.M., et al. (2020). Hypofractionated Breast Radiotherapy for 1 Week versus 3 Weeks (FAST - Forward): 5 - Year Results. LancetBenefits of Adopting Hypofractionated Radiotherapy as a Standard of Care inLow-and Middle-Income Countries,Ryan D. Kraus, MD1; Christopher R. Weil, MD1; and May Abdel-Wahab, MD, PhD2 Keywords: Ultra-Hypofractionated Operational Efficiency Digital Poster 1891 Optimal Radiotherapy Utilization Rates in Rectal Cancer: A Scoping Review Gonzalo Ulloa 1 , Raúl Aguilar-Barrientos 2,3 , Pablo Munoz-Schuffenegger 1,3 1 Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile. 2 Institute of Public Health Policies (IPSUSS), Facultad de medicina y ciencias Universidad
Made with FlippingBook - Share PDF online